Natco Pharma
Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India, and among the country's top three producers of hepatitis C drugs.
In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013. In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar. In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.
In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.
